EUVIMEDEUVIMED entdecken
Crossref

Spesolimab in the FDA Adverse Event Reporting System: A Disproportionality Analysis

Ahmet Uğur Atılan, Niyazi çetin

Journal of Pharmacy Technology · 21.11.2026

DOI: 10.1177/87551225261508397 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Pharmacy Technology, online erschienen am 21.11.2026. Verfasst von Ahmet Uğur Atılan und 1 weiteren Autor:innen. Die Arbeit nennt 5 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Atılan, A. U., & çetin, N. (2026). Spesolimab in the FDA Adverse Event Reporting System: A Disproportionality Analysis. Journal of Pharmacy Technology. https://doi.org/10.1177/87551225261508397

Vancouver

Atılan AU, çetin N. Spesolimab in the FDA Adverse Event Reporting System: A Disproportionality Analysis. Journal of Pharmacy Technology. 2026. doi:10.1177/87551225261508397

BibTeX
@article{Atlan2026,
  author = {Atılan, Ahmet Uğur and çetin, Niyazi},
  title = {Spesolimab in the FDA Adverse Event Reporting System: A Disproportionality Analysis},
  journal = {Journal of Pharmacy Technology},
  year = {2026},
  doi = {10.1177/87551225261508397}
}
Kostenlos starten →